附文獻丨艾美捷InVivoPlus抗小鼠CTLA-4 (CD152)介紹
The 9H10 monoclonal antibody reacts with mouse CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. CTLA-4 is a 33 kDa cell surface receptor encoded by the Ctla4 gene that belongs to the CD28 family of the Ig superfamily. CTLA-4 is expressed on activated T and B lymphocytes. CTLA-4 is structurally similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to the B7 family members B7-1 (CD80) and B7-2 (CD86). Upon ligand binding, CTLA-4 negatively regulates cell-mediated immune responses. CTLA-4 plays roles in induction and/or maintenance of immunological tolerance, thymocyte development, and regulation of protective immunity. The critical role of CTLA-4 in immune down-regulation has been demonstrated in CTLA-4 deficient mice, which succumb at 3-5 weeks of age due to the development of a lymphoproliferative disease. CTLA-4 is among a group of inhibitory receptors being explored as cancer treatment targets through immune checkpoint blockade. The 9H10 antibody has been shown to promote T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding.
?
9H10單克隆抗體與小鼠CTLA-4(細胞毒性T淋巴細胞抗原-4)反應,也稱為CD152。CTLA-4是由Ctla33基因編碼的4 kDa細胞表面受體,屬于Ig超家族的CD28家族。CTLA-4在活化的T和B淋巴細胞上表達。CTLA-4在結構上與T細胞共刺激蛋白CD28相似,并且兩種分子都與B7家族成員B7-1(CD80)和B7-2(CD86)結合。配體結合后,CTLA-4負調(diào)節(jié)細胞介導的免疫反應。CTLA-4在誘導和/或維持免疫耐受、胸腺細胞發(fā)育和保護性免疫調(diào)節(jié)中發(fā)揮作用。CTLA-4在免疫下調(diào)中的關鍵作用已在CTLA-4缺陷小鼠中得到證實,由于淋巴組織增生性疾病的發(fā)展,這些小鼠在3-5周齡時死亡。CTLA-4是一組通過免疫檢查點阻斷作為癌癥治療靶點的抑制受體之一。9H10抗體已被證明通過阻斷CTLA-4與B7共受體的結合來促進T細胞共刺激,從而允許CD28結合。

艾美捷InVivoPlus抗小鼠CTLA-4 (CD152)?#BP0131、#BP0032規(guī)格:
同種型?敘利亞倉鼠IgG
推薦的同種型對照?體內(nèi)加多克隆敘利亞倉鼠?IgG
推薦的稀釋緩沖液?體內(nèi)純?pH 7.0 稀釋緩沖液
免疫原?小鼠CTLA-4-人IgG1融合蛋白
報告的應用程序?體內(nèi)CTLA-4 體外中和 CTLA-4 中和
蛋白質(zhì)印跡
配方?PBS,pH 7.0
不含穩(wěn)定劑或防腐劑
內(nèi)毒素*?<1EU/mg (<0.001EU/μg)
通過LAL凝膠凝血測定法測定
集合體*?<5%
由?DLS 確定
純度?>95%
由?SDS-PAGE 決定
無?菌?0.2 μM 過濾
生產(chǎn)?從無動物設施中的組織培養(yǎng)上清液中純化
純化?蛋白?G
里德?AB_10950184
分子量?150 千達
小鼠病原體檢測*?外切粒菌/鼠痘病毒: 陰性 漢坦病毒: 陰性 K 病毒: 陰性乳酸脫氫酶升高病毒: 陰性 淋巴細胞性脈絡叢腦膜炎病毒: 陰性小鼠腺病毒: 陰性小鼠巨細胞病毒: 陰性小鼠肝炎病毒: 陰性小鼠分鐘病毒: 陰性小鼠諾如病毒: 陰性小鼠細小病毒: 陰性
小鼠輪狀病毒:肺支原體陰性:陰性?小鼠肺炎病毒:陰性?多瘤病毒:陰性呼腸孤病毒篩查:陰性?仙臺病毒:陰性?泰勒鼠腦脊髓炎:陰性
存儲?抗體溶液應以4°C的儲備濃度儲存。 不要凍結。
?
InVivoPlus抗小鼠CTLA-4 (CD152)?部分文獻引用:
in vivo CTLA-4 neutralization
Hervieu, A., et al. (2013). "Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth" J Invest Dermatol 133(2): 499-508.
?
in vivo CTLA-4 neutralization
Goding, S. R., et al. (2013). "Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma" J Immunol 190(9): 4899-4909.
?
in vivo CTLA-4 neutralization
Waitz, R., et al. (2012). "Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy" Cancer Res 72(2): 430-439.
?
in vivo CTLA-4 neutralization
Balachandran, V. P., et al. (2011). "Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido" Nat Med 17(9): 1094-1100.